Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overal... (ofight cancer. The Company applies its e...)

Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival

Date:2/14/2008

o fight cancer. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Active cellular immunotherapy holds promise because it may provide patients with a meaningful clinical benefit, such as survival, combined with low toxicity. The Company has its headquarters in Seattle, Washington and is traded on the NASDAQ Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com.

Except for historical information contained herein, this news release contains forward-looking statements that are subject to risks and uncertainties surrounding the efficacy of PROVENGE to treat men suffering from prostate cancer, risks and uncertainties surrounding the presentation of data to the FDA and approval of product applications by the FDA and risks and uncertainties inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. Factors that may cause such differences include risks related to our limited operating history, risks associated with completing our clinical trials, the risk that the safety and/or efficacy results of existing clinical trials or from additional clinical trials for PROVENGE will not support approval for a biologics license, the risk that the FDA may interpret data differently than we do or require more data or a more rigorous analysis of data than expected, the risk that the FDA will not approve a product for which a biologics license has been applied, the risk that the results of a clinical trial for PROVENGE or other product may not be indicative of results obtained in a later clinical trial, risks that we may lack the financial resources and access to capital to fund required clinical trials or commercialization of PROVENGE, our dep
'/>"/>

SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4
Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
3. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
4. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
5. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
6. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
7. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
8. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
9. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
10. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
11. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference

Post Your Comments:

(Date:5/22/2012)... Vanda Pharmaceuticals Inc. (NASDAQ: VNDA ), ... commercialization of products for central nervous system disorders, ... at the Society for Research on Biological Rhythms ... The first poster entitled Pleiomorphic Expression of ... insight into the challenges faced by individuals suffering ...

(Date:5/22/2012)... ALLEGAN, Mich., May 22, 2012 Perrigo Company ... final approval from the U.S. Food and Drug ... for butoconazole nitrate 2% vaginal cream, the generic ... submit a substantially complete ANDA with a paragraph ... marketing exclusivity. Perrigo is working exclusively with KV Pharmaceutical ...

(Date:5/22/2012)... Generics, a division of Prodigy Health Supplier Corporation ... generic equivalent of the branded drug Camptosar by ... Laboratories to develop a portfolio of oncology products. ... developed through the partnership that will add consistent ... market, which has experienced record levels of shortages ...

Breaking Medicine Technology:Vanda Pharmaceuticals Inc. Presents Scientific Posters at Society for Research on Biological Rhythms (SRBR) Annual Meeting 2 Vanda Pharmaceuticals Inc. Presents Scientific Posters at Society for Research on Biological Rhythms (SRBR) Annual Meeting 3 Perrigo Receives FDA Approval for Butoconazole Nitrate 2% Vaginal Cream 2 Perrigo Receives FDA Approval for Butoconazole Nitrate 2% Vaginal Cream 3 GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 19815 1 GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 19815 2 GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 19815 3 GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 19815 4 ULURU Inc Announces the Engagement of Gilford Securities Incorporated to Serve as the Companys Financial Advisor 18324 1 ULURU Inc Announces the Engagement of Gilford Securities Incorporated to Serve as the Companys Financial Advisor 18324 2 MAP Pharmaceuticals to Present Data on LEVADEX AE at the 15th Congress of the International Headache Society 18320 1 MAP Pharmaceuticals to Present Data on LEVADEX AE at the 15th Congress of the International Headache Society 18320 2 MAP Pharmaceuticals to Present Data on LEVADEX AE at the 15th Congress of the International Headache Society 18320 3 MAP Pharmaceuticals to Present Data on LEVADEX AE at the 15th Congress of the International Headache Society 18320 4

[0] Vanda Pharmaceuticals Inc. Presents Scientific Posters at Society for Research on Biological Rhythms (SRBR) Annual Meeting [0] Perrigo Receives FDA Approval for Butoconazole Nitrate 2% Vaginal Cream [0] Prodigy Generics and eVenus Announce the Launch of Oncology Injectable Irinotecan.

... blood ... flow, muscle oxygen supply, HOBOKEN, N.J., Oct. 17 ... reveals Pycnogenol(R),(pic-noj-en-all), an antioxidant plant extract from the bark of the ... which leads to an increase in blood flow and oxygen supply,to ...

... Joint Venture Between Bristol-Myers Squibb, Company ... in HIV Treatment -, PRINCETON, N.J. and ... Company (NYSE: BMY ) and Gilead Sciences, ... Canada has approved ATRIPLA(R),(efavirenz 600 mg/emtricitabine 200 mg/tenofovir ...

New Study: Pine Bark Extract Boosts Nitric Oxide (NO) Production Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV

(Date:5/23/2012)... second edition of Law and the American Health Care ... 2012. Building on its 1997 predecessor, the second edition ... intersection of law and the U.S. health care system. ... a time of unprecedented change in how health care ... of study, the book focuses on how a dramatically ...

(Date:5/23/2012)... of the same kind, thereby triggering skeletal and cardiac ... from the RUB Heart and Diabetes Center NRW in ... an interdisciplinary research project with colleagues from the universities ... Journal of Biological Chemistry . , One ... stabilizing filaments inside of the cells. Different mutations in ...

(Date:5/23/2012)... FRANCISCO The number of viral infections during infancy ... to a new study from researchers in the Netherlands. ... later in childhood, this association was due in part ... in infancy, particularly rhinovirus, are thought to be a ... unclear whether this association is due to the viruses ...

(Date:5/23/2012)... present findings on prostate cancer risk, screening, treatment ... of the American Urological Association May 19-23 in ... to provide expert comment for reporters covering the ... presented and their embargo dates include: , ... surgery hormone therapy , Embargoed until 10:30 a.m. ...

(Date:5/22/2012)... MAYWOOD, Ill. -- Children born with cleft lip, ... medical challenges beyond appearance. , Patients can face ... well as social and psychological challenges, Laura Swibel ... colleagues write in the June 2012 issue of ... "The management of patients with craniofacial syndromes is ...

Breaking Medicine News(10 mins):Health News:Landmark textbook on health care and the US legal system released 2 Health News:Aggregating instead of stabilizing: New insights into the mechanisms of heart disease 2 Health News:Viral infections in infancy are not associated with wheezing symptoms in later childhood 2 Health News:Mayo Clinic urologists present findings at American Urological Association Annual Meeting 2 Health News:Mayo Clinic urologists present findings at American Urological Association Annual Meeting 3 Health News:Mayo Clinic urologists present findings at American Urological Association Annual Meeting 4 Health News:Cleft lip/palate cause much more than cosmetic problems 2

[0] Landmark textbook on health care and the US legal system released [0] Aggregating instead of stabilizing: New insights into the mechanisms of heart disease [0] Viral infections in infancy are not associated with wheezing symptoms in later childhood [0] Mayo Clinic urologists present findings at American Urological Association Annual Meeting [0] Cleft lip/palate cause much more than cosmetic problems

... Inc. (NYSE: CSV ) today announced results for the first quarter ended March 31, 2009. Highlights from continuing operations for ... in millions, except per share amounts) , , ... Q1, ... Change, ...

... Inc.,s parent company, Team Finance LLC (the "Company"), today announced ... less provision for uncollectibles ("revenue less provision") in the first ... million in the first quarter of 2008. Same contract ... million from $305.5 million in the same period a year ...

... of these meds with their doctor, cardiac group says ... takes the clot-preventing drug Plavix after receiving a stent ... medications called proton pump inhibitors (PPIs), if possible, a ... blockbuster acid reflux medications such as Nexium, Prevacid and ...

... Contributions emphasize need for improved mental health services ... The Regence Foundation announced today it awarded $390,000 ... Idaho, Oregon, Utah and Washington. Five of the ... organizations nominated by Regence employees as part of ...

... age of those hospitalized in U.S. is 15, CDC says ... majority of U.S. cases continue to be mild, those who ... atypically young, health officials said Wednesday. , In fact, the ... which is younger than occurs in regular seasonal flu, U.S. ...

... The following was released today by Americans for ... National Institute for Occupational Safety and Health (NIOSH) ... dangerous levels of secondhand smoke at work. NIOSH recommends ... casinos is safe for workers to breathe. In 2005, ...

Carriage Services Announces First Quarter 2009 Results Team Finance LLC Announces First Quarter 2009 Results Plavix, Heartburn Drugs May Be Risky Combination Regence Foundation Grants $390,000 to Improve Health Care Safety Net Younger Age of Severe Swine Flu Cases Worries Experts No Safe Bets for Casino Workers: NIOSH Study Shows Casino Workers Face Toxic Conditions

Slick® Disposable Endotracheal Stylet, Nylon-coated wire, Malleable core, Sureloc Stop helps maintain desired length for patient safety. Handle forming capability for better grip. Sterile. Single...

Stylet - Infant Stainless Steel, Flexible, Non-Sterile, Latex Free, With stop, Suitable for tubes 2.0 mm I.D. or larger....

... two groups of flexible lighting products. The ... in three different sizes 5", 10", and ... of the light). These lights are for ... needed., ,The second group of flexible ...

All endotracheal accessories are designed to ensure your technique. The Blue Line® intubation stylets feature a satin-smooth coating and are available in three sizes....

Medicine Products:

Slick® Disposable Endotracheal Stylet 6 Fr Endotracheal Tube Stylet - Infant Lighted Pediatric Stylet - Sterile Blue Line® Intubation Stylet 5.0 mm 7.0 mm

Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overal...(ofight cancer. The Company applies its e...),Health